Delayed
Nasdaq
16:00:00 2024-04-02 EDT
|
5-day change
|
1st Jan Change
|
2.65
USD
|
-0.38%
|
|
-.--%
|
+11.81%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
1,724
|
774.3
|
269.4
|
111.7
|
Enterprise Value (EV)
1 |
1,327
|
415.8
|
7.248
|
-49.46
|
P/E ratio
|
-7.53
x
|
-8.61
x
|
-2.31
x
|
-0.98
x
|
Yield
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-36,936,822
x
|
-4,620,558
x
|
-61,463
x
|
418,419
x
|
EV / FCF
|
-77,130,730
x
|
-10,617,201
x
|
-142,619
x
|
834,896
x
|
FCF Yield
|
-0%
|
-0%
|
-0%
|
0%
|
Price to Book
|
4.4
x
|
2.43
x
|
1.21
x
|
0.7
x
|
Nbr of stocks (in thousands)
|
43,327
|
43,696
|
44,165
|
47,113
|
Reference price
2 |
39.78
|
17.72
|
6.100
|
2.370
|
Announcement Date
|
21-03-29
|
22-03-28
|
23-03-15
|
24-03-28
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-35.92
|
-89.99
|
-117.9
|
-118.2
|
EBIT
1 |
-7.63
|
-12.01
|
-36
|
-90.11
|
-118.5
|
-119
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-7.63
|
-9.938
|
-35.76
|
-89.76
|
-116.3
|
-112.6
|
Net income
1 |
-7.63
|
-9.938
|
-35.76
|
-89.76
|
-116.3
|
-112.6
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-2.091
|
-2.716
|
-5.284
|
-2.059
|
-2.639
|
-2.419
|
Free Cash Flow
|
-
|
-5.91
|
-17.2
|
-39.16
|
-50.82
|
-59.24
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-11-03
|
20-11-03
|
21-03-29
|
22-03-28
|
23-03-15
|
24-03-28
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
7
|
76.5
|
397
|
359
|
262
|
161
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-5.91
|
-17.2
|
-39.2
|
-50.8
|
-59.2
|
ROE (net income / shareholders' equity)
|
-
|
-23.9%
|
-15.3%
|
-24%
|
-37.9%
|
-53.9%
|
ROA (Net income/ Total Assets)
|
-
|
-17.5%
|
-9.41%
|
-14.7%
|
-22.9%
|
-32.9%
|
Assets
1 |
-
|
56.71
|
380
|
611.6
|
506.7
|
342.6
|
Book Value Per Share
2 |
2.090
|
-4.770
|
9.050
|
7.280
|
5.040
|
3.380
|
Cash Flow per Share
2 |
1.920
|
20.90
|
8.410
|
3.410
|
1.240
|
1.210
|
Capex
|
-
|
-
|
0.3
|
0.77
|
2.72
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-11-03
|
20-11-03
|
21-03-29
|
22-03-28
|
23-03-15
|
24-03-28
|
|
1st Jan change
|
Capi.
|
---|
| +11.81% | 125M | | +23.13% | 52.73B | | +37.49% | 39B | | -8.73% | 38.52B | | +28.09% | 30.38B | | -12.26% | 26.39B | | +10.57% | 26.08B | | +45.05% | 14.15B | | +32.23% | 12.6B | | -6.56% | 11.51B |
Other Biotechnology & Medical Research
|